Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 251

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 251
---
 the Class I directors are                                                                         
 Mr. Byrnes and Ms. Rolfe, and their terms will expire at our 2025 annual meeting of stockholders; |

| ● | the Class II directors                                                                                      
 are Mr. Atwood and Ms. LaPorte, and their terms will expire at our 2026 annual meeting of stockholders; and |

| ● | the Class III directors                                                                                
 are Mr. Ehrlich and Mr. Patel, and their terms will expire at our 2027 annual meeting of stockholders. |

<div align='center'>145</div>

Our Bylaws provide that
the number of members of our board of directors shall be fixed in accordance with our Charter. Our Charter provides that the authorized
number of directors may be changed only by resolution of the board of directors. Any additional directorships resulting from an increase
in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third
of the directors. Our board of directors is currently fixed at seven members. The division of our board of directors into three classes
with staggered three-year terms may delay or prevent a change of our board of directors or a change in control of our company. Our directors
may be removed only for cause by the affirmative vote of the holders of at least two-thirds of our outstanding voting stock then entitled
to vote in an election of directors.

Director Attendance at Annual Meeting of Stockholders

We encourage our directors
to attend our annual meetings of stockholders. We did not hold an annual meeting of stockholders during the fiscal year ended December
31, 2023.

Board and Committee Meetings

During the fiscal year ended
December 31, 2023, our board of directors met four times, our Audit Committee met four times, our Compensation Committee and our
nominating and corporate governance committee met zero times. Each board member attended 75% or more of the aggregate number of meetings
of the board of directors and meetings of the committees on which he or she served during the fiscal year ended December 31, 2023,
for which he or she was a director or committee member.

Board Leadership Structure

Our board of directors does
not have a policy regarding separation of the roles of Chief Executive Officer and chairman of the board of directors. Our board of directors
recognizes that it is important to determine an optimal board leadership structure to ensure the independent oversight of management
as we continue to grow, and believes it